EUCTR2022-002989-33-DE进行中（未招募）1 期
CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY:THE COLPRIT PHASE I/II STUDY - COLPRIT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically proven diagnosis of one of the following active measurable lymphoproliferative malignancies (as defined in chapter 10.1):
- •a) Multiple myeloma (progression after conventional chemotherapy, at least one proteasome inhibitor and one immunomodulatory drug, and high-dose chemotherapy with autoSCT, not currently suitable for allogeneic hematopoietic stem cell transplantation [alloSCT])
- •b) Aggressive B- and T-NHL including heavily pretreated transformed indolent lymphoma (tNHL) (refractory or relapsed disease after extensive pretreatment with min. 2 regimes, at least one including an anti-CD20 antibody, or after standard high-dose chemotherapy with autoSCT), not currently suitable for alloSCT
- •2. Inclusion of patients with preceded CAR-T cell therapy is allowed but not a perquisite if such a therapy is not indicated or available at the time point of inclusion
- •3. Positive 68Ga -Pentixafor PET/CT imaging. In patients with MM 68Ga-Pentixafor-PET/CT may be replaced by 68Ga-Pentixafor-PET/MR
- •4. Bone marrow aspirate and biopsy (according to clinical routine from last lymphom/myelom specific therapy or 3 - 4 months prior to Baseline) for assessment of pathology, cytology and immunohistochemistry and/or flow cytometry for CXCR4 (CD184) expression
- •5. Availability of CD34+ peripheral blood hematopoietic stem cells (CD34+ HSC), > 2x106 CD34+HSC / kg body weight) prior to enrolment, obtained during a previous treatment line, including HSC intended for backup use
- •6. Age = 18 years
- •7. Eastern cooperative oncology group (ECOG) performance status 0-1 and life expectancy > 3 months and deemed fit for high-dose chemotherapy and autologous stem-cell transplantation
- •8. Adequate hematopoetic, hepatic (ALAT/ASAT <5x ULN, total Bilirubin <2.5x ULN), renal (CreaCl>40ml/min), cardiac and pulmonary function, excluding organ dysfunctions associated with the underlying disease.
- •9. Women of childbearing potential (WOCBP) must be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test. Acceptable methods of birth control with a low failure rate (i.e. less than 1% per year) when used consistently and correct are for example implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence (defined as refraining from heterosexual intercourse during the clinical trial) or vasectomized partner. Those contraceptive measures should be applied for 30 days after visit 3
- •Men with child bearing potential (CBP) must either use a condom, must be vasectomized or stay sexual abstinent (defined as refraining from heterosexual intercourse during the clinical trial). Contraception for WOCBP – as above mentioned – should be considered. Those contraceptive measures should be applied for 90 days after visit 3.
- •10. Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Evidence of active concurrent malignant disease
- •2. Evidence of rapid progress of underlying diseases with severely limited life expectancy (< 3 months)
- •3. Evidence of significant, uncontrolled acute or chronic concomitant diseases that could affect compliance with the protocol or interpretation of results including contraindications against CT-/MRI-/PET-Scans or against myeloablative therapy followed by autoSCT
- •4. Study participants with discrepant lesions in FDG PET cannot be included
- •5. Uncontrolled active or chronic infection, including hepatitis B and/or C (Anti-HbS, HbS-AG) and HIV (Anti-HIV)
- •6. Patients with a history of psychiatric illness or condition that could interfere with their ability to understand the requirements of the clinical trial
- •7. Previous or concurrent participation in another clinical study involving trial medication within the preceding 12 weeks (prior to Baseline) or previous participation in this clinical trial
- •8. Pregnancy or breast-feeding women
- •9. Known hypersensitivity to the IMP or NIMP/AxMP or any agent given in association with this clinical trial
研究者
相似试验
已完成
不适用
Assessment of CXC chemokine receptor type 4 (CXCR4) expression as a predictive marker on the effect of leukocytapheresis for ulcerative colitisulcerative colitisJPRN-UMIN000005718Kyoto University Hospital20
进行中（未招募）
不适用
A study of the efficacy of POL6326 in treating patients following a heart attackMedDRA version: 18.0Level: LLTClassification code 10064345Term: ST segment elevation myocardial infarctionSystem Organ Class: 100000004849Acute Myocardial InfarctionEUCTR2012-003229-91-HUPolyphor AG140
进行中（未招募）
不适用
A study of the efficacy of POL6326 in treating patients following a heart attackAcute Myocardial InfarctionEUCTR2012-003229-91-DEPolyphor AG140
进行中（未招募）
不适用
A study of the efficacy of POL6326 in treating patients following a heart attackAcute Myocardial InfarctionEUCTR2012-003229-91-PLPolyphor AG140
进行中（未招募）
不适用
A study of the efficacy of POL6326 in treating patients following a heart attackAcute Myocardial InfarctionEUCTR2012-003229-91-HRPolyphor AG140